SLC5A2 and hydrops fetalis: The proposed mechanisms of action of SGLT2 inhibitors in HF patients include but are not limited to diuresis from glycosuria and natriuresis as a result of inhibition of the sodium-glucose transporter in the proximal renal tubule, improving the energy source for cardiac metabolism of the failing heart by aiding the liver in ketogenesis, possible anti-inflammatory properties and hindering adverse cardiac remodeling [13].